Explore Next-Generation Sequencing (NGS) Technology

NGS-based RNA sequencing is a cutting-edge technology that has revolutionized the study of gene expression and transcriptomics. This method leverages the capabilities of NGS to provide a comprehensive and detailed analysis of the RNA molecules present in a sample offering insights into gene expression, alternative splicing, and also the presence of non-coding RNAs.

Offering a thorough understanding of transcriptome dynamics and gene expression, next-generation sequencing (NGS-based RNA-sequencing) is a potent and revolutionary technique in genomics.

According to Prophecy Market Insights, the global NGS-based RNA-sequencing market size and share is projected to grow from USD 2.1 Billion in 2024 and is forecasted to reach USD 11.1 Billion by 2034, exhibiting a compound annual growth rate (CAGR) of 18.10% during the forecast period (2024 - 2034).

The NGS-Based RNA-Sequencing Market is characterized by rapid growth, technological innovation, and fierce competition. Companies are expanding their global presence, focusing on sustainability, and diversifying their service offerings to stay competitive.

Some of the Key Market Players:

• Illumina
• Thermo Fischer Scientific
• Oxford Nanopore
• Agilent Technologies, Inc.
• BGI
• Perkinelmer Inc.
• QIAGEN
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd.
• Takara Bio Inc.

The market for RNA sequencing is growing as genomics and personalized medicine gain more attention. Particularly in the fields of oncology, neurology, and infectious illness, researchers and physicians are using RNA sequencing to better understand disease mechanisms, discover biomarkers, and obtain insights into gene expression.   

Growth in Omics Research

• A crucial part of multi-omics methods is RNA-sequencing which allows researchers to combine information from proteomics, metabolomics, transcriptomic, and genomes. Demand for RNA-sequencing thorough transcriptome analysis is rising as omics research expands.

Focus on Single-Cell RNA-Sequencing

• ScRNA-seq, or single-cell RNA sequencing, is becoming more popular because it makes it possible to analyze gene expression at the single-cell level. This method is being employed more in developmental biology, immunology, and cancer research, offering greater insights into cellular heterogeneity.     

Recent Development:

• In March 2023, a package comprising Illumina products and the GenoScreen Deeplex Myc-TB assay, a targeted next-generation sequencing (NGS) test for the comprehensive and quick identification of anti-TB medication resistance, was released by Illumina Inc. and GenoScreen. This will contribute to the World Health Organization's (WHO) 2035 global tuberculosis epidemic plan.

Regional Insights

• North America: Leading research institutes, biotechnology businesses as well as pharmaceutical corporations that are at the forefront of implementing and developing NGS technologies are heavily concentrated in North America.     
• Asia Pacific: This region is experiencing a surge in the biotechnology industry with a growing number of biotech startups and established companies adopting NGS technologies.

Avail the Sample Report PDF Here